A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Since 1995, National HIV Testing Day has raised awareness and confronted stereotypes about HIV. Learn about HIV testing options and prevention methods.

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.